🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and China registers with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company as lead sponsor. Synced 26 Sep 2026
14Current trials
9Recruiting now
21Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 14 current clinical trials in our USA, UK and China registers. 9 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Cyclophosphamide, Fludarabine and Zola-cel. The most-studied condition is Systemic Sclerosis.

ClinicalTrials.gov trials by status

  • Recruiting964%
  • Not yet open214%
  • Active, closed321%

Trials by phase

  • Phase 1536%
  • Phase 2429%
  • Observational321%
  • Phase 3214%
01

Clinical trials sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
NCT06788652 · Mantle Cell Lymphoma (MCL)
Observational Recruiting 2025-02 USA
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 3 Recruiting 2025-03 UK, USA, China
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06153251 · Relapsed and/or Refractory Multiple Myeloma
Phase 1 Recruiting 2024-01 USA
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
NCT06788639 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Observational Recruiting 2025-02 USA
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226 · ClinicalTrials.gov ↗ · Multiple Myeloma
Phase 2 Recruiting 2024-03 USA
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843 · ClinicalTrials.gov ↗ · Multiple Myeloma
Phase 1 Recruiting 2024-02 USA
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
NCT06794268 · ClinicalTrials.gov ↗ · Follicular Lymphoma
Observational Recruiting 2025-02 USA
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
NCT07115745 · ClinicalTrials.gov ↗ · Refractory Autoimmune Diseases
Phase 1 Recruiting 2025-09 USA
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242 · ClinicalTrials.gov ↗ · Lymphoma
Phase 2 Recruiting 2025-11 USA
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
NCT07603557 · ClinicalTrials.gov ↗ · Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Phase 2 Not yet open 2026-08 UK, USA
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562 · ClinicalTrials.gov ↗ · Systemic Sclerosis
Phase 3 Not yet open 2027-02 UK, USA
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983 · ClinicalTrials.gov ↗ · Lupus Erythematosus, Systemic, Lupus Nephritis
Phase 2 Active, closed 2025-07 UK, USA
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
NCT06220201 · ClinicalTrials.gov ↗ · Multiple Sclerosis, Myasthenia Gravis
Phase 1 Active, closed 2024-03 UK, USA
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Phase 1 Active, closed 2023-09 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Juno Therapeutics, Inc., a Bristol-Myers Squibb Company trials

21 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Juno Therapeutics, Inc., a Bristol-Myers Squibb Company trials

19 conditions
Systemic Sclerosis2Multiple Myeloma2Relapsed or Refractory Multiple Myeloma (RRMM)1Lupus Erythematosus, Systemic1Lupus Nephritis1Chronic Immune Thrombocytopenia1Autoimmune Hemolytic Anemia1Multiple Sclerosis1Myasthenia Gravis1Mantle Cell Lymphoma (MCL)1Relapsed and/or Refractory Multiple Myeloma1Chronic Lymphocytic Leukemia (CLL)1Small Lymphocytic Lymphoma (SLL)1Follicular Lymphoma1Systemic Lupus Erythematosus1Idiopathic Inflammatory Myopathy1Rheumatoid Arthritis1Refractory Autoimmune Diseases1Lymphoma1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA149
Clinical trials in UK51
Clinical trials in China11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Systemic Sclerosis

SponsorTrials
Nanjing Bioheng Biotech3

Sponsors with the most current trials registered for this condition.

06

Questions about Juno Therapeutics, Inc., a Bristol-Myers Squibb Company trials

How many clinical trials does Juno Therapeutics, Inc., a Bristol-Myers Squibb Company sponsor?

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 14 current trials on ClinicalTrials.gov in our USA, UK and China registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Juno Therapeutics, Inc., a Bristol-Myers Squibb Company trials recruiting?

Yes. 9 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company testing?

Its current trials name 21 drugs and biologicals as interventions. The most frequent are Cyclophosphamide (8), Fludarabine (7), Zola-cel (5), Lisocabtagene maraleucel (3) and BMS-986393 (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.